<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982930</url>
  </required_header>
  <id_info>
    <org_study_id>CTBM100C2303E1</org_study_id>
    <secondary_id>EudraCT 2008-004764-39</secondary_id>
    <nct_id>NCT00982930</nct_id>
  </id_info>
  <brief_title>Open Label Extension to Bridging Study CTBM100C2303</brief_title>
  <official_title>A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is an open-label, single arm (uncontrolled) study in subjects suffering from cystic
      fibrosis, who have completed their study participation in CTBM100C2303 (all visits) and who
      were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of tobramycin inhalation powder for the treatment of infections with P. aeruginosa in subjects suffering from cystic fibrosis.</measure>
    <time_frame>Each visit during the 168-day treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of tobramycin inhalation powder, assessed by spirometry</measure>
    <time_frame>Each visit during the 168-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of microorganisms in sputum samples</measure>
    <time_frame>Each visit (except last visit) during the 168-day treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Pseudomonas Aeruginosa</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>TIPnew</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin inhalation powder</intervention_name>
    <description>Tobramycin inhaled powder</description>
    <arm_group_label>TIPnew</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed all visits in study CTBM100C2303, and visit 4 took place not more than 5
             days before enrollment into this study.

          -  Confirmed diagnosis of cystic fibrosis patients with P. aeruginosa infection.

          -  FEV1 at screening (study CTBM100C2303) must be between 25% and 80% of normal predicted
             values.

        Exclusion Criteria:

          -  Any use of inhaled anti-pseudomonal antibiotics between the termination of the core
             trial CTMB100C2303 and the enrollment into this study.

          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7403</url>
    <description>CTBM100C2303E1 Results at Novartis Clinical Trials Results Website</description>
  </link>
  <results_reference>
    <citation>Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr;51(4):372-8. doi: 10.1002/ppul.23358. Epub 2015 Dec 27.</citation>
    <PMID>26709158</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobramycin Inhalation Powder</keyword>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Lung diseases</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

